Literature DB >> 10492405

Axillary brachial plexus block with ropivacaine 7.5 mg/ml. A comparative study with bupivacaine 5 mg/ml.

J C Raeder1, S Drøsdahl, O Klaastad, O Kvalsvik, B Isaksen, K E Strømskag, P Mowinckel, R Bergheim, D Selander.   

Abstract

BACKGROUND: Ropivacaine is less cardiotoxic than bupivacaine and may be used in higher doses in order to increase the quality of a block. The aim of this study was to compare the efficacy and safety of 40 ml ropivacaine 7.5 mg/ml (300 mg) and 40 ml bupivacaine 5 mg/ml (200 mg) for axillary plexus block.
METHODS: One hundred and four adult patients were included in a prospective, double-blind study. Sensory and motor block were tested for the five main terminal nerves of the arm at 10-min intervals until start of surgery and every second hour there-after until full resolution of the block.
RESULTS: The overall evaluation of the block by the surgeon and the anesthesiologist showed a significantly better quality in the ropivacaine patients, regarding both anesthesia and motor block. There were no differences in the time to onset and duration of the block. Except for one patient, who had seizures after an accidental IV injection of ropivacaine, there were no major side effects.
CONCLUSION: Ropivacaine 7.5 mg/ml, 40 ml, produces axillary plexus block of similar onset and duration but better quality than 40 ml of bupivacaine 5.0 mg/ml.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10492405     DOI: 10.1034/j.1399-6576.1999.430802.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  7 in total

Review 1.  Ropivacaine: a review of its use in regional anaesthesia and acute pain management.

Authors:  Dene Simpson; Monique P Curran; Vicki Oldfield; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Pharmacokinetics and efficacy of 40 ml ropivacaine 7.5 mg/ml (300 mg), for axillary brachial plexus block--an open pilot study.

Authors:  W Wank; J Büttner; K Rissler Maier; B M Emanuelson; D Selander
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.441

Review 3.  Benefit-risk assessment of ropivacaine in the management of postoperative pain.

Authors:  Wolfgang Zink; Bernhard M Graf
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  High dose ropivacaine-induced toxicity after infraclavicular block.

Authors:  Chun Woo Yang; Po Soon Kang; Hee Uk Kwon; Dae Jin Lim
Journal:  Korean J Anesthesiol       Date:  2012-01-25

5.  Ropivacaine-induced toxicity with overdose suspected after axillary brachial plexus block.

Authors:  Yoshinobu Kimura; Yasuhiro Kamada; Akira Kimura; Kaori Orimo
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

6.  Ropivacaine: A review of its pharmacology and clinical use.

Authors:  Gaurav Kuthiala; Geeta Chaudhary
Journal:  Indian J Anaesth       Date:  2011-03

7.  Sympatholytic and Anti-Inflammatory Effects of Ropivacaine and Bupivacaine After Infraclavicular Block in Arterio Venous Fistula Surgery.

Authors:  Faranak Behnaz; Pardis Soltanpoor; Houman Teymourian; Niki Tadayon; Gholam Reza Mohseni; Mahshid Ghasemi
Journal:  Anesth Pain Med       Date:  2019-02-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.